Background. Rapid molecular tests combined with Antimicrobial Stewardship Program (ASP) interventions have provided opportunities to optimize patient outcomes and reduce unnecessary antimicrobial use. Our institution currently uses an FDA approved influenza/respiratory syncytial virus polymerase chain reaction (PCR) assay and multiplex respiratory panel. In addition, our institution commonly utilizes procalcitonin (PCT) levels. The ASP at Summa Health System -Akron Campus (SHS-AC) routinely recommends use of these rapid diagnostic tests to assist with antimicrobial and antiviral usage, including the discontinuation of antibiotics in influenza positive patients in the absence of a concurrent bacterial infection.
Methods. A retrospective review of all ASP interventions on influenza positive patients at SHS-AC was performed from December 2017 to March 2018. The ASP reviewed all patients on broad-spectrum antibiotics >48 hours and all influenza positive patients without Infectious Disease consultation. The appropriateness of antimicrobial and antiviral therapy was assessed, including assessment of culture and PCR results, PCT levels, indication of therapy, and renal function. For patients with a positive influenza PCR and low PCT without evidence of bacterial infection, the recommendation was to discontinue antibacterial use. Data collected included: intervention type, acceptance rate, PCT levels, and influenza subtype.
Results. Two hundred thirty-three total recommendations were made by the ASP on influenza positive patients, with a 96.6% acceptance rate. Interventions included the following: obtain PCT level (54/233), de-escalate or stop antibiotics based on culture, PCR, and PCT results (116/233), obtain influenza or respiratory PCR (8/233), initiate oseltamivir (37/233), and other (18/233).
Conclusion. ASP intervention combined with PCT levels and PCR results contributed to the reduction of unnecessary antibiotic use, and the initiation of oseltamivir therapy in influenza-positive patients.
Disclosures. Background. Rapid diagnostic testing (RDT) for Gram-positive blood cultures has previously shown to significantly decrease time to appropriate antibiotic therapy as compared with traditional microbiological methods. Implementation of RDT with antimicrobial stewardship team (AST) notification may significantly improve RDT use and decrease time to optimal therapy; however, in community hospitals with limited resources AST notification may not be feasible. This study aimed to determine the impact of RDT implementation without AST notification on time to appropriate antibiotic therapy for blood cultures growing Gram-positive cocci (GPC) in clusters in a community teaching hospital.
Methods. A retrospective quasi-experimental study was conducted evaluating adult inpatients with a blood culture positive for GPC in clusters. The primary outcome of this study was to compare the time to appropriate therapy for Staphylococcal bacteremia in the pre-RDT group (January 1-June 30, 2016) vs. post-RDT group (January 1-June 30, 2017). Secondary endpoints included comparing the number of anti-MRSA doses administered to patients whose cultures grew coagulase-negative staphylococcus (CoNS) determined contaminants and length of stay (LOS) between groups.
Results. Two hundred fifty-two patients were included in the study (pre-RDT n = 143, post-RDT n = 109). There were 58 patients with Staphylococcus aureus bacteremia (SAB) and 194 patients with CoNS. Mean time to active therapy for SAB following Gram-stain result was similar between groups (pre-RDT 4.1 hours vs. post-RDT 1.06 hours, P = 0.157). The median time to discontinuation of antibiotics for CoNS contaminants was significantly decreased in the post-RDT group (26.38 vs. 8.27 hours, P = 0.006) and the median number of anti-MRSA doses was also significantly decreased (1 vs. 0 dose, P = 0.003). In the post-RDT group, significantly fewer patients with CoNS cultures had empiric anti-MRSA therapy ordered after Gram-stain (50% vs. 24.4%, P = 0.042). Mean LOS was significantly shorter for patients with CoNS contaminants in the post-RDT group (10.1 vs. 7.5 days, P = 0.036).
Conclusion. Implementation of the RDT without AST notification significantly improved time to de-escalation, decreased empiric anti-MRSA antibiotic exposure, and resulted in significantly shorter LOS for patients with CoNS contaminated blood cultures.
Disclosures. All authors: No reported disclosures. to pharmacy-managed surveillance software for AST review and intervention. The primary outcome was time to optimal therapy (TOT) from initial culture positivity. Secondary outcomes included TOT based on organism and clinical pharmacy staffing hours, hospital length of stay, and all-cause mortality. Results. Among 324 patients screened with a first episode of GN BSI, 121 and 119 patients were included in the pre-and post-intervention groups, respectively. Apart from intensive care unit admission at the time of culture collection, there were no significant differences in baseline characteristics between the two groups. The post-intervention group had a significantly shorter TOT (60.2 ± 36.0 hours vs. 29.0 ± 24.0 hours, P < 0.001). Notably, time to escalation for patients with third-generation cephalosporin-resistant isolates was significantly shorter in the post-intervention group (48 ± 36.0 hours vs. 19.2 ± 16.8 hours, P < 0.01). In the post-intervention group, TOT was significantly shorter during fully staffed clinical pharmacy hours vs. reduced clinical pharmacy staff hours (18.48 ± 31.2 hours vs. 31.44 ± 38.4 hours, P = 0.014). No differences were seen in length of stay or all-cause mortality.
The Impact of Rapid Diagnostic Testing and Antimicrobial Stewardship on the Time to Escalation/De-escalation of Antimicrobial Regimens for GramNegative Bloodstream Infections at a Large Community Hospital
Conclusion. The implementation of RDT with a pharmacy-driven AST substantially decreased TOT for GN BSIs. This study also highlights the positive impact of clinical pharmacy staff on shorter TOTs.
Disclosures. All authors: No reported disclosures. Results. Mean patient age and Charlson comorbidity index was not significantly different between 2017 and 2018. Time to obtain culture, delivery to Microbiology, and Gram-stain was not different between the two groups. Time to organism ID was significantly faster in 2018 (2018, 25.2 ± 13.7; 2017, 34 .2 ± 17 hours, P = 0.001). Time to AST results was also significantly faster for patients in 2018 compared with 2017 (19.8 ± 14.1 compared with 28.5 ± 15.1 hours, P = 0.001). ASP recommended significantly more adjustments to empiric antimicrobial therapy (25% of 2018 vs. 1% in 2017, P < 0.001). In addition, length of hospital stay was significantly shorter for patients in 2018 compared with 2017 (2018, 8.3 ± 7 days; 2017, 15.6 ± 18 .3 days, P < 0.001). Finally, in-hospital length of antimicrobial therapy was significantly shorter in 2018 compared with 2017 (2018, 6.6 ± 3.7 days; 2017, 8.8 ± 7 .7 days, P < 0.05).
Matrix-Assisted Laser
Conclusion. The use of MALDI-TOF/Vitek 2 leads to an average 18 hours faster microbial ID and AST results. ASP is able to make recommendations for infectious diseases management more appropriately with quicker ID and AST results.
Disclosures. 
